This site uses cookies

To give you the best possible experience, the GAM website uses cookies. You can read full information of our cookie use here. Your privacy is important to us and we encourage you to read our privacy policy here.


Jenna Denyes

Dr Jenna Denyes - Healthcare Analyst

Dr Jenna Denyes, Healthcare Analyst, is responsible for scientific analysis of the global healthcare sector and a member of the Healthcare Equity investment team.

Prior to joining GAM Investments in September 2019, Jenna was an Account Manager with, a medical communication consulting company where she managed multiple global pharmaceutical account teams. Prior to this she was an academic researcher focused on bringing advances in genomics and proteomics from the bench top to the market with the development of diagnostic tools. Jenna holds a PhD from the ETH Zurich, Switzerland, and an MSc and BSc Hons from the University of Guelph, Canada. She is based in Zurich.

Dr Jenna Denyes

My Insights

Investment Opinions

10 min read

Beyond the sound bites: How can a positive readout be so complex?
13 July 2021

Three positive trial results in the biotechnology space have led to very different market reactions. Dr Jenna Denyes, Senior Healthcare Analyst, looks beyond the headlines to understand the reasons behind these diverse outcomes.

Investment Opinions

07:48 min watch

GAM ACTs on equitable Covid-19 response
15 March 2021

Dr Jenna Denyes, Senior Healthcare Analyst, details the significance of GAM signing up to an initiative aimed at allowing access to Covid-19 vaccines and examines the role of sustainability in healthcare sector investments.

Investment Opinions

5 min read

mRNA: The final frontier of genetic medicine
27 January 2021

GAM Investments’ Dr Jenna Denyes discusses the validation of mRNA technology and how it is set to drive the pace of innovation in the genetic medicine space.

Investment Opinions

4 min read

mRNA tech takes a giant leap forward
11 November 2020

GAM Investments’ Dr Jenna Denyes examines the encouraging Covid-19 vaccine news in detail and discusses the possible implications for mRNA therapies and the wider healthcare sector.